**Supplementary Table 4. Summary of median (Q1, Q3) fasting metabolic assessments and change from baseline at weeks 48 and 144 (Studies GS-US-320-0108 and GS-US-320-0110 pooled safety analysis, double‑blind phase)**

| Metabolic Assessmenta | TAF 25 mg (N = 227) | TDF 300 mg (N = 107) | *p*‑Valueb |
| --- | --- | --- | --- |
| Fasting Total Cholesterol (mg/dL) |  |  |  |
| Baseline |  |  |  |
| N | 227 | 107 | 0.913 |
| Median | 174 | 174 |  |
| Q1, Q3 | 150, 197 | 152, 193 |  |
| Change at Week 48 |  |  |  |
| N | 217 | 102 | <0.001 |
| Median | –3 | −22 |  |
| Q1, Q3 | −17, 14 | −38, −9 |  |
| Change at Week 144 |  |  |  |
| N | 212 | 99 | <0.001 |
| Median | –8 | −27 |  |
| Q1, Q3 | −21, 12 | −40, −10 |  |
| Fasting Direct LDL Cholesterol (mg/dL) |  |  |  |
| Baseline |  |  |  |
| N | 227 | 107 | 0.675 |
| Median | 108 | 112 |  |
| Q1, Q3 | 92, 128 | 89, 127 |  |
| Change at Week 48 |  |  |  |
| N | 217 | 102 | <0.001 |
| Median | 0 | −10 |  |
| Q1, Q3 | −10, 16 | −25, 1 |  |
| Change at Week 144 |  |  |  |
| N | 212 | 99 | <0.001 |
| Median | 11 | −5 |  |
| Q1, Q3 | −4, 25 | −15, 7 |  |
| Fasting HDL Cholesterol (mg/dL) |  |  |  |
| Baseline |  |  |  |
| N | 227 | 107 | 0.441 |
| Median | 57 | 55 |  |
| Q1, Q3 | 46, 68 | 46, 66 |  |
| Change at Week 48 |  |  |  |
| N | 217 | 102 | <0.001 |
| Median | –4 | –10 |  |
| Q1, Q3 | −10, 2 | −16, –2 |  |
| Change at Week 144 |  |  |  |
| N | 212 | 99 | 0.012 |
| Median | –8 | –12 |  |
| Q1, Q3 | −15, -2 | −18, -5 |  |
| Fasting Total Cholesterol to HDL Ratio |  |  |  |
| Baseline |  |  |  |
| N | 227 | 107 | 0.682 |
| Median | 3.0 | 3.1 |  |
| Q1, Q3 | 2.6, 3.7 | 2.6, 3.8 |  |
| Change at Week 48 |  |  |  |
| N | 217 | 102 | 0.040 |
| Median | 0.2 | 0.1 |  |
| Q1, Q3 | –0.1, 0.6 | −0.2, 0.4 |  |
| Change at Week 144 |  |  |  |
| N | 212 | 99 | 0.042 |
| Median | 0.4 | 0.3 |  |
| Q1, Q3 | 0.0, 0.8 | −0.1, 0.6 |  |
| Fasting Triglycerides (mg/dL) |  |  |  |
| Baseline |  |  |  |
| N | 227 | 107 | 0.798 |
| Median | 97 | 95 |  |
| Q1, Q3 | 73, 118 | 69, 116 |  |
| Change at Week 48 |  |  |  |
| N | 217 | 102 | <0.001 |
| Median | 3 | −19 |  |
| Q1, Q3 | −16, 31 | −33, 0 |  |
| Change at Week 144 |  |  |  |
| N | 212 | 99 | <0.001 |
| Median | 11 | –6 |  |
| Q1, Q3 | −14, 41 | −28, 15 |  |

Change = Change from baseline.

aOnly laboratory measurements under fasting status were summarized.

b*p*-values were from the 2-sided Wilcoxon rank sum test to compare the treatment groups.